CT-2106

Camptothecins are an important and fast growing class of anti-cancer drugs. However, like taxanes, their full benefit is limited by poor solubility and significant toxicity. We have been developing a novel polyglutamate-camptothecin molecule, CT-2106 with phase I/II studies in colorectal and ovarian cancers.

We have delayed development of CT-2106 and have no clinical trial material for additional trials. We are presently focusing our resources on the development of XYOTAX™ and pixantrone.

CT-2106 Clinical Trials

In April 2004, we initiated a phase I/II clinical trial of CT-2106 in combination with infusional 5 fluorouracil/folinic acid, or 5-FU/FA, in patients with metastatic colorectal cancer who have failed front-line therapy with oxaliplatin. We also initiated a phase II clinical trial of CT-2106 as a single-agent in ovarian cancer at the end of 2004.

We presented preliminary phase I data on CT-2106 at the EORTC-NCI-AACR conference in September 2004. The data showed that CT-2106 was well-tolerated and lacked the severe gastrointestinal side effects, or diarrhea, and bladder or hematuria toxicities, which are typical for camptothecins.

CT-2106 References (18k PDF)